BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

FibroGen, Inc. 

225 Gateway Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-866-7200 Fax: 650-866-7202


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
FibroGen, Inc. Announces Patient Enrollment In New Phase 2 Clinical Study Of FG-3019 For The Treatment Of Idiopathic Pulmonary Fibrosis 12/20/2013 9:43:04 AM    More...
FibroGen, Inc. Announces Observations Of Possible Disease Stabilization And Improvement In Interim Analysis Of Phase 2 Study Of FG-3019 As Treatment For Idiopathic Pulmonary Fibrosis 11/27/2013 8:53:53 AM    More...
FibroGen, Inc. Reports Data From Phase 2 Hemoglobin Correction Study of Roxadustat (FG-4592) in Chinese Patients With Chronic Kidney Disease 11/12/2013 11:27:09 PM    More...
FibroGen, Inc. Announces Analysis Of Peritoneal Dialysis Patients With Chronic Kidney Disease From Roxadustat (FG-4592) Incident Dialysis Study 11/12/2013 11:16:43 PM    More...
FibroGen, Inc. to Present Data for Roxadustat (FG-4592), an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Oral Presentations at American Society of Nephrology - Kidney Week 2013 11/5/2013 7:08:37 AM    More...
AstraZeneca PLC (AZN) Bets $815 Million on FibroGen, Inc.'s Anemia Drug 7/31/2013 6:45:26 AM    More...
FibroGen, Inc. and Astellas Pharma Inc. (YPH.BE) Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease 12/12/2012 9:26:14 AM    More...
FibroGen, Inc. Reports Data from Phase 2 Study of FG-4592 Hemoglobin Correction and Maintenance in End-Stage Renal Patients 11/5/2012 9:58:21 AM    More...
FibroGen, Inc. Announces Results Showing That FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), Corrects Anemia Without Intravenous Iron Supplementation in Incident Dialysis Patients 11/5/2012 9:56:59 AM    More...
FibroGen, Inc. to Present Phase 2 Data for FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), at American Society of Nephrology Kidney Week 2012 11/1/2012 8:31:35 AM    More...
1234567